Sopherion Therapeutics Announces Completion Of Enrollment In Phase III Study Of Myocet In Metastatic Breast Cancer

News — By on March 19, 2009 at 3:00 am

Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced that it completed enrollment in its pivotal Phase III study of nonpegylated liposomal doxorubicin (Myocet(TM)) in metastatic HER-2-overexpressing breast cancer. This is a pivotal Phase III trial of Sopherion’s lead product in combination with the current standard of care, paclitaxel (Taxol) and trastuzumab (Herceptin(R)), vs.

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback